Literature DB >> 30445205

Mitosis perturbation by MASTL depletion impairs the viability of thyroid tumor cells.

Elena Cetti1, Tiziana Di Marco1, Giuseppe Mauro1, Mara Mazzoni1, Daniele Lecis2, Emanuela Minna1, Lucia Gioiosa3, Silvia Brich4, Sonia Pagliardini1, Maria Grazia Borrello1, Giancarlo Pruneri5, Maria Chiara Anania1, Angela Greco6.   

Abstract

Even if thyroid tumors are generally curable, a fraction will develop resistance to therapy and progress towards undifferentiated forms, whose treatment remains a demanding challenge. To identify potential novel targets for treatment of thyroid cancer, in a previous study using siRNA-mediated functional screening, we identified several genes that are essential for the growth of thyroid tumor, but not normal cells. Among the top-ranking hits, we found microtubule associated serine/threonine kinase-like (MASTL), which is known to play an essential role in mitosis regulation, and is also involved in the DNA damage response. Herein, we examine the effects of MASTL depletion on growth and viability of thyroid tumor cells. MASTL depletion impaired cell proliferation and increased the percentage of cells presenting nuclear anomalies, which are indicative of mitotic catastrophe. Furthermore, MASTL depletion was associated with enhanced DNA damage. All these effects eventually led to cell death, characterized by the presence of apoptotic markers. Moreover, MASTL depletion sensitized thyroid tumor cells to cisplatin. Our results demonstrate that MASTL represents vulnerability for thyroid tumor cells, which could be explored as a therapeutic target for thyroid cancer.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  MASTL; Mitotic catastrophe; Non-oncogene addiction; Target validation; Thyroid tumor cells

Mesh:

Substances:

Year:  2018        PMID: 30445205     DOI: 10.1016/j.canlet.2018.11.010

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  5 in total

1.  Therapeutic natural compounds Enzastaurin and Palbociclib inhibit MASTL kinase activity preventing breast cancer cell proliferation.

Authors:  Aneesha Polisety; Gauri Misra; Jyotika Rajawat; Amit Katiyar; Harpreet Singh; Anant Narayan Bhatt
Journal:  Med Oncol       Date:  2022-05-23       Impact factor: 3.738

2.  MASTL promotes cell contractility and motility through kinase-independent signaling.

Authors:  Maria Emilia Taskinen; Elisa Närvä; James R W Conway; Laura Soto Hinojosa; Sergio Lilla; Anja Mai; Nicola De Franceschi; Laura L Elo; Robert Grosse; Sara Zanivan; Jim C Norman; Johanna Ivaska
Journal:  J Cell Biol       Date:  2020-06-01       Impact factor: 10.539

Review 3.  PP2A-B55 Holoenzyme Regulation and Cancer.

Authors:  Perrine Goguet-Rubio; Priya Amin; Sushil Awal; Suzanne Vigneron; Sophie Charrasse; Francisca Mechali; Jean Claude Labbé; Thierry Lorca; Anna Castro
Journal:  Biomolecules       Date:  2020-11-22

Review 4.  MASTL: A novel therapeutic target for Cancer Malignancy.

Authors:  Iram Fatima; Amar B Singh; Punita Dhawan
Journal:  Cancer Med       Date:  2020-07-21       Impact factor: 4.452

5.  The Greatwall kinase safeguards the genome integrity by affecting the kinome activity in mitosis.

Authors:  Xavier Bisteau; Joann Lee; Vinayaka Srinivas; Joanna H S Lee; Joanna Niska-Blakie; Gifford Tan; Shannon Y X Yap; Kevin W Hom; Cheng Kit Wong; Jeongjun Chae; Loo Chien Wang; Jinho Kim; Giulia Rancati; Radoslaw M Sobota; Chris S H Tan; Philipp Kaldis
Journal:  Oncogene       Date:  2020-09-25       Impact factor: 8.756

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.